Liquidia Corporation (NASDAQ:LQDA) is praised by Raymond James for YUTREPIA’s 75% growth in U.S. prostacyclin revenue, leading to a raised price target of $47 and a “Strong Buy” rating. The company reported Q3 2025 results, including $51.7 million in net sales for YUTREPIA and positive adjusted EBITDA of $10.1 million.

Despite a net loss of $3.5 million, Liquidia Corporation (NASDAQ:LQDA) ended Q3 2025 with $157.5 million in cash and reported positive early launch performance for YUTREPIA. The company is exploring additional clinical applications in IPF and PPF, with strong payer coverage achieved through contracts with major commercial payers.

Liquidia Corporation (NASDAQ:LQDA) focuses on developing therapies for pulmonary arterial hypertension and related cardiopulmonary diseases using its proprietary PRINT and TRIA platforms. The company ended Q3 2025 with $157.5 million in cash and is exploring additional clinical applications in IPF and PPF.

While Liquidia Corporation (NASDAQ:LQDA) shows promise, some AI stocks may offer greater upside potential with less downside risk. Investors seeking undervalued AI stocks can explore opportunities that benefit from Trump-era tariffs and the onshoring trend.

Read more at Yahoo Finance: Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA’s 75% Growth in U.S. Prostacyclin Revenue